Jane Street Group LLC Has $391,000 Stake in Tango Therapeutics, Inc. (NASDAQ:TNGX)

Jane Street Group LLC lessened its stake in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) by 26.3% during the third quarter, Holdings Channel reports. The fund owned 50,764 shares of the company’s stock after selling 18,126 shares during the quarter. Jane Street Group LLC’s holdings in Tango Therapeutics were worth $391,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of TNGX. The Manufacturers Life Insurance Company increased its stake in Tango Therapeutics by 8.1% in the second quarter. The Manufacturers Life Insurance Company now owns 29,511 shares of the company’s stock valued at $253,000 after purchasing an additional 2,218 shares in the last quarter. Point72 DIFC Ltd bought a new stake in Tango Therapeutics in the 2nd quarter valued at about $54,000. China Universal Asset Management Co. Ltd. raised its stake in Tango Therapeutics by 64.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 20,607 shares of the company’s stock worth $159,000 after buying an additional 8,055 shares during the period. Quest Partners LLC boosted its holdings in Tango Therapeutics by 1,448.4% in the third quarter. Quest Partners LLC now owns 10,885 shares of the company’s stock worth $84,000 after acquiring an additional 10,182 shares in the last quarter. Finally, Principal Financial Group Inc. acquired a new stake in Tango Therapeutics in the second quarter valued at approximately $90,000. Institutional investors and hedge funds own 78.99% of the company’s stock.

Insider Buying and Selling at Tango Therapeutics

In other news, Director Mace Rothenberg bought 10,000 shares of the stock in a transaction on Thursday, November 14th. The shares were purchased at an average cost of $3.62 per share, for a total transaction of $36,200.00. Following the completion of the purchase, the director now directly owns 21,250 shares in the company, valued at $76,925. This represents a 88.89 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Boxer Capital Management, Llc sold 3,080,000 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $3.14, for a total value of $9,671,200.00. Following the transaction, the insider now owns 3,610,642 shares of the company’s stock, valued at $11,337,415.88. The trade was a 46.03 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 4,338,000 shares of company stock worth $18,426,160. Insiders own 6.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on TNGX shares. HC Wainwright reaffirmed a “buy” rating and set a $13.00 target price on shares of Tango Therapeutics in a research report on Friday, November 8th. B. Riley dropped their price objective on shares of Tango Therapeutics from $16.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, November 11th. Guggenheim reduced their price objective on shares of Tango Therapeutics from $18.00 to $8.00 and set a “buy” rating for the company in a report on Thursday, November 7th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Tango Therapeutics in a report on Thursday, December 5th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $13.14.

Tango Therapeutics Price Performance

Shares of TNGX stock opened at $3.47 on Wednesday. The firm has a 50-day moving average of $3.62 and a 200-day moving average of $7.06. Tango Therapeutics, Inc. has a one year low of $2.70 and a one year high of $13.01. The company has a market cap of $372.74 million, a P/E ratio of -2.94 and a beta of 0.81.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.